Top Markets
Coin of the day
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Kedudukan dalam Saham #25524
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Harga Saham
$9.81
Disegerakkan terakhir: 2025-03-18
Modal Pasaran
$48.68M
Perubahan (1 hari)
1.55%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan AlloVir, Inc. (ALVR)

Kategori

Sejarah hasil dividen untuk AlloVir, Inc. (ALVR)
Hasil dividen (TTM) bagi AlloVir, Inc. (simbol saham: ALVR) pada 2023-12-31 adalah: 0.00%
Purata hasil dividen 5 tahun terakhir: 0.00%
Sejarah hasil dividen untuk AlloVir, Inc. (ALVR) dari 2022 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Ubah
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
Hasil dividen (TTM) untuk syarikat serupa atau pesaing
Syarikat Hasil Dividen Negara
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH
0.00%
US